Imidazo[4,5-c]Pyridine Compounds for Selective TLR7/8 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new Toll-like receptor (TLR) agonists to treat diseases such as cancer and viral infections effectively.
Innovation Solution
Development of imidazo[4,5-c]pyridine derivatives that act as selective TLR7/8 modulators, providing therapeutic agents for immunomodulation, viral infection prevention or treatment, and cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TLR agonists (such as imiquimod) are used, then antitumor activity and immune response are enhanced, but the need for new selective TLR7/8 modulators indicates limitations in current therapy effectiveness or specificity
Solution Approach 1:
The patent modifies the chemical structure of TLR agonists by changing molecular parameters (imidazo[4,5-c]pyridine core structure with specific substituents at positions R1-R12) to achieve selective activation of TLR7/8 receptors, thereby improving therapeutic effectiveness while enhancing selectivity compared to existing agonists like imiquimod
2Power
If TLR8 activation is achieved, then cytokine production (IL-12, IL-18, TNF-α, IFN-γ) and immune responses are amplified, but potential off-target effects or toxicity may occur
Solution Approach 1:
The patent designs compounds with specific local structural features (imidazo[4,5-c]pyridine core with positioned substituents R1-R12) that enable selective binding to TLR7/8 receptors, ensuring that immune response amplification occurs locally at the target receptor without causing widespread off-target effects or toxicity
Data Source
AI summary
Disclosed herein are immune response modulators that act on toll-like receptors and methods of use thereof.